Signature biomarkers in Crohn's disease

Toward a molecular classification

Razvan Arsenescu, M. E.C. Bruno, E. W. Rogier, A. T. Stefka, A. E. McMahan, T. B. Wright, M. S. Nasser, W. J.S. de Villiers, C. S. Kaetzel

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In an effort to develop a molecular classification scheme for Crohn's disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls were analyzed for expression of the RelA subunit of nuclear factor (NF)-κB, A20 (a negative regulator of NF-κB), polymeric immunoglobulin receptor (pIgR), tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis was used to classify individuals into three subsets based on patterns of biomarker expression. Set 1 included normal subjects and CD patients with mild disease and good responses to therapy, thus defining "normal" biomarker expression. CD patients in set 2, characterized by low expression of all five biomarkers, had moderate to severe disease and poor responses to immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute inflammation that responded well to therapy. Classification of CD patients by these biomarkers may predict disease behavior and responses to therapy.

Original languageEnglish (US)
Pages (from-to)399-411
Number of pages13
JournalMucosal Immunology
Volume1
Issue number5
DOIs
StatePublished - Aug 29 2008
Externally publishedYes

Fingerprint

Crohn Disease
Biomarkers
Polymeric Immunoglobulin Receptors
Tumor Necrosis Factor-alpha
Interleukin-8
Therapeutics
Immunosuppressive Agents
Principal Component Analysis
Inflammation
Biopsy

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Arsenescu, R., Bruno, M. E. C., Rogier, E. W., Stefka, A. T., McMahan, A. E., Wright, T. B., ... Kaetzel, C. S. (2008). Signature biomarkers in Crohn's disease: Toward a molecular classification. Mucosal Immunology, 1(5), 399-411. https://doi.org/10.1038/mi.2008.32
Arsenescu, Razvan ; Bruno, M. E.C. ; Rogier, E. W. ; Stefka, A. T. ; McMahan, A. E. ; Wright, T. B. ; Nasser, M. S. ; de Villiers, W. J.S. ; Kaetzel, C. S. / Signature biomarkers in Crohn's disease : Toward a molecular classification. In: Mucosal Immunology. 2008 ; Vol. 1, No. 5. pp. 399-411.
@article{a04a9e075acc48e1bfdc4b462a2e7b77,
title = "Signature biomarkers in Crohn's disease: Toward a molecular classification",
abstract = "In an effort to develop a molecular classification scheme for Crohn's disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls were analyzed for expression of the RelA subunit of nuclear factor (NF)-κB, A20 (a negative regulator of NF-κB), polymeric immunoglobulin receptor (pIgR), tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis was used to classify individuals into three subsets based on patterns of biomarker expression. Set 1 included normal subjects and CD patients with mild disease and good responses to therapy, thus defining {"}normal{"} biomarker expression. CD patients in set 2, characterized by low expression of all five biomarkers, had moderate to severe disease and poor responses to immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute inflammation that responded well to therapy. Classification of CD patients by these biomarkers may predict disease behavior and responses to therapy.",
author = "Razvan Arsenescu and Bruno, {M. E.C.} and Rogier, {E. W.} and Stefka, {A. T.} and McMahan, {A. E.} and Wright, {T. B.} and Nasser, {M. S.} and {de Villiers}, {W. J.S.} and Kaetzel, {C. S.}",
year = "2008",
month = "8",
day = "29",
doi = "10.1038/mi.2008.32",
language = "English (US)",
volume = "1",
pages = "399--411",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "5",

}

Arsenescu, R, Bruno, MEC, Rogier, EW, Stefka, AT, McMahan, AE, Wright, TB, Nasser, MS, de Villiers, WJS & Kaetzel, CS 2008, 'Signature biomarkers in Crohn's disease: Toward a molecular classification', Mucosal Immunology, vol. 1, no. 5, pp. 399-411. https://doi.org/10.1038/mi.2008.32

Signature biomarkers in Crohn's disease : Toward a molecular classification. / Arsenescu, Razvan; Bruno, M. E.C.; Rogier, E. W.; Stefka, A. T.; McMahan, A. E.; Wright, T. B.; Nasser, M. S.; de Villiers, W. J.S.; Kaetzel, C. S.

In: Mucosal Immunology, Vol. 1, No. 5, 29.08.2008, p. 399-411.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Signature biomarkers in Crohn's disease

T2 - Toward a molecular classification

AU - Arsenescu, Razvan

AU - Bruno, M. E.C.

AU - Rogier, E. W.

AU - Stefka, A. T.

AU - McMahan, A. E.

AU - Wright, T. B.

AU - Nasser, M. S.

AU - de Villiers, W. J.S.

AU - Kaetzel, C. S.

PY - 2008/8/29

Y1 - 2008/8/29

N2 - In an effort to develop a molecular classification scheme for Crohn's disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls were analyzed for expression of the RelA subunit of nuclear factor (NF)-κB, A20 (a negative regulator of NF-κB), polymeric immunoglobulin receptor (pIgR), tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis was used to classify individuals into three subsets based on patterns of biomarker expression. Set 1 included normal subjects and CD patients with mild disease and good responses to therapy, thus defining "normal" biomarker expression. CD patients in set 2, characterized by low expression of all five biomarkers, had moderate to severe disease and poor responses to immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute inflammation that responded well to therapy. Classification of CD patients by these biomarkers may predict disease behavior and responses to therapy.

AB - In an effort to develop a molecular classification scheme for Crohn's disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls were analyzed for expression of the RelA subunit of nuclear factor (NF)-κB, A20 (a negative regulator of NF-κB), polymeric immunoglobulin receptor (pIgR), tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis was used to classify individuals into three subsets based on patterns of biomarker expression. Set 1 included normal subjects and CD patients with mild disease and good responses to therapy, thus defining "normal" biomarker expression. CD patients in set 2, characterized by low expression of all five biomarkers, had moderate to severe disease and poor responses to immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute inflammation that responded well to therapy. Classification of CD patients by these biomarkers may predict disease behavior and responses to therapy.

UR - http://www.scopus.com/inward/record.url?scp=50149098200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149098200&partnerID=8YFLogxK

U2 - 10.1038/mi.2008.32

DO - 10.1038/mi.2008.32

M3 - Article

VL - 1

SP - 399

EP - 411

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 5

ER -

Arsenescu R, Bruno MEC, Rogier EW, Stefka AT, McMahan AE, Wright TB et al. Signature biomarkers in Crohn's disease: Toward a molecular classification. Mucosal Immunology. 2008 Aug 29;1(5):399-411. https://doi.org/10.1038/mi.2008.32